Nothing Special   »   [go: up one dir, main page]

HUE058142T2 - Amino-pirimidin SSAO inhibitorok - Google Patents

Amino-pirimidin SSAO inhibitorok

Info

Publication number
HUE058142T2
HUE058142T2 HUE17838647A HUE17838647A HUE058142T2 HU E058142 T2 HUE058142 T2 HU E058142T2 HU E17838647 A HUE17838647 A HU E17838647A HU E17838647 A HUE17838647 A HU E17838647A HU E058142 T2 HUE058142 T2 HU E058142T2
Authority
HU
Hungary
Prior art keywords
amino pyrimidine
ssao inhibitors
ssao
inhibitors
pyrimidine
Prior art date
Application number
HUE17838647A
Other languages
English (en)
Inventor
David Andrew Coates
Luo Heng Qin
Yi Wei
Jingye Zhou
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE058142T2 publication Critical patent/HUE058142T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE17838647A 2016-08-12 2017-08-04 Amino-pirimidin SSAO inhibitorok HUE058142T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/094833 WO2018027892A1 (en) 2016-08-12 2016-08-12 Amino pyrimidine ssao inhibitors

Publications (1)

Publication Number Publication Date
HUE058142T2 true HUE058142T2 (hu) 2022-07-28

Family

ID=61161335

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17838647A HUE058142T2 (hu) 2016-08-12 2017-08-04 Amino-pirimidin SSAO inhibitorok

Country Status (23)

Country Link
US (3) US10287270B2 (hu)
EP (2) EP3984996B1 (hu)
JP (2) JP7035013B2 (hu)
KR (3) KR102483876B1 (hu)
CN (2) CN108884056B (hu)
AU (2) AU2017309199B2 (hu)
BR (1) BR112019002275A2 (hu)
CA (1) CA3033687A1 (hu)
CR (1) CR20190124A (hu)
DK (2) DK3984996T3 (hu)
ES (1) ES2908805T3 (hu)
HU (1) HUE058142T2 (hu)
IL (1) IL264745B (hu)
MA (1) MA45937A (hu)
MX (1) MX2019001581A (hu)
MY (1) MY196576A (hu)
NZ (1) NZ750290A (hu)
PH (1) PH12019500296A1 (hu)
PL (1) PL3497086T3 (hu)
PT (1) PT3497086T (hu)
SG (1) SG11201900844UA (hu)
WO (2) WO2018027892A1 (hu)
ZA (2) ZA201901097B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) * 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CA3112510A1 (en) * 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US20210353608A1 (en) * 2018-10-29 2021-11-18 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
TW202039486A (zh) * 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
MX2021006724A (es) * 2019-01-11 2021-11-04 Transthera Sciences Nanjing Inc Compuestos de halo-alilamina y uso de los mismos.
BR112022007974A2 (pt) 2019-10-29 2022-07-12 Eccogene Shanghai Co Ltd Inibidores de ssao e uso dos mesmos
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
US20230127498A1 (en) * 2020-03-25 2023-04-27 Terns, Inc. Treatment of respiratory disorders
IL298145A (en) * 2020-05-13 2023-01-01 Terns Pharmaceuticals Inc Combined treatment of liver disorders
KR20230058112A (ko) 2020-08-25 2023-05-02 일라이 릴리 앤드 캄파니 Ssao 억제제의 다형체
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
KR20220145981A (ko) 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
TW202327589A (zh) * 2021-11-11 2023-07-16 美商拓臻製藥公司 肝病之組合療法
US20230181583A1 (en) * 2021-11-11 2023-06-15 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
WO2008123469A1 (ja) 2007-03-30 2008-10-16 Japan Tobacco Inc. 6員環アミド化合物およびその用途
AU2008280784A1 (en) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2008327615B2 (en) 2007-11-21 2014-08-21 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
JP2011136942A (ja) * 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
EA025839B1 (ru) 2011-03-15 2017-02-28 Астеллас Фарма Инк. Гуанидиновые соединения, полезные для предотвращения и/или лечения диабетической нефропатии или диабетического отека желтого пятна
SG10201707020TA (en) 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
WO2014078609A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
US8962641B2 (en) * 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014184104A1 (en) * 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Also Published As

Publication number Publication date
KR20190038580A (ko) 2019-04-08
EP3497086B1 (en) 2021-12-15
SG11201900844UA (en) 2019-02-27
CA3033687A1 (en) 2018-02-15
NZ750290A (en) 2022-09-30
KR102483876B1 (ko) 2023-01-03
BR112019002275A2 (pt) 2019-06-18
EP3497086A4 (en) 2020-03-25
AU2017309199A1 (en) 2019-02-21
US10287270B2 (en) 2019-05-14
AU2022203071B2 (en) 2024-06-20
DK3984996T3 (da) 2024-10-21
PT3497086T (pt) 2022-03-14
EP3984996A1 (en) 2022-04-20
CR20190124A (es) 2019-05-13
CN114380801A (zh) 2022-04-22
EP3497086A1 (en) 2019-06-19
WO2018028517A1 (en) 2018-02-15
KR102646063B1 (ko) 2024-03-12
CN108884056A (zh) 2018-11-23
JP2019527717A (ja) 2019-10-03
PL3497086T3 (pl) 2022-05-02
CN108884056B (zh) 2022-01-07
MY196576A (en) 2023-04-19
JP7372957B2 (ja) 2023-11-01
MA45937A (fr) 2019-06-19
ZA201901097B (en) 2022-08-31
JP2022003049A (ja) 2022-01-11
DK3497086T3 (da) 2022-03-14
IL264745B (en) 2021-08-31
WO2018027892A1 (en) 2018-02-15
MX2019001581A (es) 2019-06-20
ZA202202097B (en) 2023-11-29
EP3984996B1 (en) 2024-10-09
US10464928B2 (en) 2019-11-05
KR20230008889A (ko) 2023-01-16
KR20240035917A (ko) 2024-03-18
AU2022203071A1 (en) 2022-05-26
PH12019500296A1 (en) 2019-05-15
US20200262817A1 (en) 2020-08-20
AU2017309199B2 (en) 2022-05-12
US20190276436A1 (en) 2019-09-12
ES2908805T3 (es) 2022-05-04
US20180297987A1 (en) 2018-10-18
US10793552B2 (en) 2020-10-06
JP7035013B2 (ja) 2022-03-14

Similar Documents

Publication Publication Date Title
ZA201901097B (en) Amino pyrimidine ssao inhibitors
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL268625A (en) Amino pyrimidine compounds used as SSAO inhibitors
IL271999A (en) TYK2 inhibitors and uses thereof
HK1248690A1 (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
HK1256997A1 (zh) Tyk2抑制劑及其用途
PT3626699T (pt) Inibidor de ssao
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
EP3149008B8 (en) Certain protein kinase inhibitors
GB201615282D0 (en) Tankyrase inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
ZA201907136B (en) Ip6k inhibitors
GB201612860D0 (en) Inhibitors
EP3186247A4 (en) Protein kinase inhibitors
ZA201808238B (en) Certain protein kinase inhibitors
EP3224248A4 (en) Certain protein kinase inhibitors
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
HK1255012A1 (zh) 含氨基酸的組合物
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201614783D0 (en) Kinases inhibitors
GB201609517D0 (en) Enzyme inhibitors